Legal & General Group Portfolio holdings
Legal & General Group Plc, founded in 1836 by six lawyers in London, is a British multinational financial services company headquartered in London, renowned for its leadership in insurance, pensions, and investment management. Managing trillions in assets, the firm operates through key divisions like Legal & General Investment Management (LGIM), one of the UK’s largest asset managers, focusing on index funds, active strategies, and sustainable investing for institutional clients like pension funds. It also provides life insurance, retirement products, and general insurance, serving millions of customers with a strong emphasis on long-term financial security and infrastructure investment, such as affordable housing. With a heritage of stability and a modern push toward ESG (environmental, social, governance) principles, Legal & General remains a cornerstone of the UK financial landscape with a growing global presence.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$657M |
| 2 |
Apple
AAPL
|
+$610M |
| 3 |
Amazon
AMZN
|
+$587M |
| 4 |
AstraZeneca
AZN
|
+$319M |
| 5 |
Snowflake
SNOW
|
+$272M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$323M |
| 2 |
MXIM
Maxim Integrated Products
MXIM
|
+$273M |
| 3 |
WORK
Slack Technologies, Inc.
WORK
|
+$121M |
| 4 |
PFPT
Proofpoint, Inc.
PFPT
|
+$98.6M |
| 5 |
JD.com
JD
|
+$89.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.03% |
| 2 | Financials | 13.72% |
| 3 | Healthcare | 12.6% |
| 4 | Consumer Discretionary | 10.97% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Impinj
PI
$5.6B
| $344K | ﹤0.01% |
6,021
+3,447
| +134% | +$176K |
|
|
LGTY
2527
DELISTED
Logility Supply Chain Solutions, Inc. Common Stock
LGTY
| $344K | ﹤0.01% |
14,452
+6,133
| +74% | +$141K |
|
2528
Green Brick Partners
GRBK
$3.14B
| $343K | ﹤0.01% |
16,710
+6,508
| +64% | +$153K |
|
2529
Aterian
ATER
$5.37M
| $341K | ﹤0.01% |
2,621
+1,888
| +258% | +$209K |
|
2530
Ocular Therapeutix
OCUL
$2.02B
| $341K | ﹤0.01% |
34,052
+12,533
| +58% | +$141K |
|
2531
Galicia Financial Group
GGAL
$7.42B
| $338K | ﹤0.01% |
33,602
+7,947
| +31% | +$72.8K |
|
|
FFWM
2532
DELISTED
First Foundation Inc
FFWM
| $336K | ﹤0.01% |
12,782
+7,503
| +142% | +$179K |
|
2533
MannKind Corp
MNKD
$1.32B
| $336K | ﹤0.01% |
77,294
+46,764
| +153% | +$211K |
|
|
MCF
2534
DELISTED
Contango Oil & Gas Co.
MCF
| $335K | ﹤0.01% |
73,525
+21,336
| +41% | +$81.3K |
|
|
IVC
2535
DELISTED
Invacare Corporation
IVC
| $334K | ﹤0.01% |
70,189
| – | – |
|
2536
Carriage Services
CSV
$569M
| $330K | ﹤0.01% |
7,390
+3,374
| +84% | +$137K |
|
2537
CVR Energy
CVI
$3.13B
| $330K | ﹤0.01% |
19,825
-14,703
| -43% | -$207K |
|
2538
1-800-Flowers.com
FLWS
$258M
| $330K | ﹤0.01% |
10,828
+6,420
| +146% | +$203K |
|
|
IDEX
2539
DELISTED
Ideanomics, Inc. Common Stock
IDEX
| $330K | ﹤0.01% |
1,341
+596
| +80% | +$174K |
|
2540
Omeros
OMER
$959M
| $329K | ﹤0.01% |
23,858
+11,477
| +93% | +$172K |
|
2541
Establishment Labs
ESTA
$2.28B
| $328K | ﹤0.01% |
4,569
+3,745
| +454% | +$276K |
|
|
VBIV
2542
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $325K | ﹤0.01% |
3,481
+1,186
| +52% | +$113K |
|
|
XOG
2543
DELISTED
Extraction Oil & Gas, Inc. Common Stock
XOG
| $325K | ﹤0.01% |
5,746
+4,094
| +248% | +$196K |
|
|
JKS
2544
JinkoSolar
JKS
$891M
| $323K | ﹤0.01% |
7,041
-22,202
| -76% | -$1.12M |
|
2545
National Healthcare
NHC
$3.38B
| $322K | ﹤0.01% |
4,593
+2,636
| +135% | +$192K |
|
|
EPZM
2546
DELISTED
Epizyme, Inc
EPZM
| $321K | ﹤0.01% |
62,767
+14,081
| +29% | +$85.5K |
|
|
NTST
2547
NETSTREIT Corp
NTST
$2.1B
| $318K | ﹤0.01% |
13,431
+7,777
| +138% | +$196K |
|
2548
C4 Therapeutics
CCCC
$412M
| $317K | ﹤0.01% |
7,091
+2,520
| +55% | +$108K |
|
2549
Precigen
PGEN
$2.59B
| $317K | ﹤0.01% |
63,575
+18,029
| +40% | +$104K |
|
2550
Theravance Biopharma
TBPH
$877M
| $316K | ﹤0.01% |
42,749
+11,224
| +36% | +$126K |
|
Similar funds
Legal & General Group's Q3 2021 Portfolio in Review
As of Q3 2021, Legal & General Group held 3,551 positions worth $308B, up 2.9% from $299B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Legal & General Group deployed $10.7B of net new capital in Q3 2021, opening 77 new positions and adding to 2,293 existing holdings. Its largest new stake was AstraZeneca: 2,738,007 shares worth $329M.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was JD.com, an estimated $89.3M trimmed.
- Legal & General Group's largest Q3 2021 buy was AstraZeneca: 2,738,007 shares worth $329M.
- Legal & General Group added most to Microsoft in Q3 2021, an estimated $657M increase.
- Legal & General Group's biggest Q3 2021 reduction was JD.com, cutting an estimated $89.3M.
- Legal & General Group fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $323M.
- Legal & General Group's ten largest holdings make up 22% of its $308B portfolio in Q3 2021.
- Legal & General Group opened 77 new positions and closed 55 in Q3 2021.
- Legal & General Group's portfolio value rose 2.9% quarter-over-quarter to $308B.
Based on Legal & General Group's 13F filing for Q3 2021, filed 15 Nov 2021.